These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 16838457

  • 1. The unfinished business of U.S. drug safety regulation.
    Evans BJ, Flockhart DA.
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract] [Full Text] [Related]

  • 2. Industry reneges on postmarketing trial commitments.
    Bouchie A.
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract] [Full Text] [Related]

  • 3. U.S. postmarketing pharmacovigilance compliance in the midst of regulatory uncertainty.
    Goldman SA.
    Food Drug Law J; 2007 Jul; 62(3):513-28. PubMed ID: 17915393
    [No Abstract] [Full Text] [Related]

  • 4. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 5. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H.
    Nat Biotechnol; 2008 May 15; 26(5):477-8. PubMed ID: 18464756
    [No Abstract] [Full Text] [Related]

  • 6. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V, Baylor NW.
    Pediatrics; 2011 May 15; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [Abstract] [Full Text] [Related]

  • 7. The impact of FDA reform.
    Trunzo J.
    Med Device Technol; 2003 Apr 15; 14(3):36-7. PubMed ID: 12789699
    [Abstract] [Full Text] [Related]

  • 8. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM.
    Am J Law Med; 1997 Apr 15; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract] [Full Text] [Related]

  • 9. Pin the tail on the other donkey: allocating and avoiding injury losses after drug or device approval.
    O'Reilly JT.
    Food Drug Law J; 2007 Apr 15; 62(3):559-72. PubMed ID: 17915397
    [No Abstract] [Full Text] [Related]

  • 10. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL.
    Food Drug Law J; 2005 Apr 15; 60(2):261-338. PubMed ID: 16094773
    [No Abstract] [Full Text] [Related]

  • 11. Paying for drug approvals--who's using whom?
    Avorn J.
    N Engl J Med; 2007 Apr 26; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract] [Full Text] [Related]

  • 12. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M.
    N Engl J Med; 2007 Apr 26; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract] [Full Text] [Related]

  • 13. Bolstering the FDA's drug-safety authority.
    Schultz WB.
    N Engl J Med; 2007 Nov 29; 357(22):2217-9. PubMed ID: 18046024
    [No Abstract] [Full Text] [Related]

  • 14. Tempered enthusiasm. Drug-safety law needs more teeth, patient-safety advocates say.
    DerGurahian J.
    Mod Healthc; 2007 Oct 08; 37(40):16. PubMed ID: 18018373
    [No Abstract] [Full Text] [Related]

  • 15. Making medicines safer--the need for an independent drug safety board.
    Wood AJ, Stein CM, Woosley R.
    N Engl J Med; 1998 Dec 17; 339(25):1851-4. PubMed ID: 9854125
    [No Abstract] [Full Text] [Related]

  • 16. Drug safety: a contrarian's point of view.
    Cobert B.
    Food Drug Law J; 2007 Dec 17; 62(3):501-12. PubMed ID: 17915392
    [No Abstract] [Full Text] [Related]

  • 17. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD.
    Issue Brief Health Policy Track Serv; 2012 Dec 31; ():1-79. PubMed ID: 23297449
    [No Abstract] [Full Text] [Related]

  • 18. FDA embraces risk-management approach.
    Fox JL.
    Nat Biotechnol; 2003 Oct 31; 21(10):1120-1. PubMed ID: 14520383
    [No Abstract] [Full Text] [Related]

  • 19. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M.
    Seton Hall Law Rev; 2007 Oct 31; 37(4):941-68. PubMed ID: 18363218
    [No Abstract] [Full Text] [Related]

  • 20. Canadian and US drug approval times and safety considerations.
    Rawson NS, Kaitin KI.
    Ann Pharmacother; 2003 Oct 31; 37(10):1403-8. PubMed ID: 14519031
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.